-
Clin. Pharmacol. Ther. · May 2017
ReviewDrug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
- G M Blumenthal, K B Goldberg, and R Pazdur.
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Clin. Pharmacol. Ther. 2017 May 1; 101 (5): 572-574.
AbstractAs a result of enhanced understanding of genetic and immunologic underpinnings of cancer, there has been progress in development of targeted and immunotherapies in oncology. The traditional linear sequential model of drug development has evolved. Early clinical trials of breakthrough therapies often include expansion cohorts, termed "seamless drug development." The US Food and Drug Administration (FDA) uses expedited programs, such as breakthrough designation and accelerated approval ensuring that transformative therapies are available to patients earlier in the cycle of evidence generation.Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..